Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
  • Latest long-term analysis, including more than three years of follow-up data of patients with Grade 2 IDH-mutant glioma treated with VORANIGO® (vorasidenib), will be presented in a rapid oral session on May 31 at 4:36 p.m. CDT
  • Results show median progression-free survival among patients treated with VORANIGO was 44.1 months
  • Findings from an exploratory analysis from the INDIGO study evaluating the impact of VORANIGO on seizure rates and quality of life will be shared in a separate poster presentation

BOSTON, May 31, 2026 /PRNewswire/ -- Servier today announced updated efficacy and safety results from more than three years of follow-up in the Phase 3 INDIGO trial evaluating VORANIGO® (vorasidenib) versus placebo in patients with Grade 2 mutant isocitrate dehydrogenase 1 or 2 (IDH1/2) glioma following surgical intervention and who are not in immediate need of chemoradiotherapy. These data, which will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on May 31 at 4:36 p.m. CDT in Chicago, strengthen the previous findings from the INDIGO pivotal trial and demonstrate the clinical benefits of VORANIGO continue to improve over time.

Recommended for you